Effects of luteolin 5-O-beta-rutinoside in streptozotocin-induced diabetic rats.
We have investigated the antidiabetic activity of luteolin 5-rutinoside in streptozotocin(STZ)-induced diabetic rats. Treatment for 20 days with 2 mg/kg increased both pancreatic insulin and DNA content. When both luteolin 5-rutinoside (2 mg/kg) and glibenclamide (1 mg/kg) were administered concurrently to STZ-diabetic rats, a marked antidiabetic activity was achieved. This effect was evidenced by a significant decrease in glycemia levels (> 50%), a 2.5-fold increase in insulin blood levels and an increase in body and pancreas weight, compared to the diabetic control group.
Zarzuelo
A
A
Departamento de Farmacología, Facultad de Farmacia, Universidad de Granada, Spain.
Jiménez
I
I
Gámez
M J
MJ
Utrilla
P
P
Fernadez
I
I
Torres
M I
MI
Osuna
I
I
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000188:drug therapy*; D005419:Flavonoids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005905:Glyburide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D047311:Luteolin; D008297:Male; D009929:Organ Size; D010179:Pancreas / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin
D001786:Blood Glucose; D005419:Flavonoids; D007004:Hypoglycemic Agents; C099684:luteolin 5-rutinoside; D013311:Streptozocin; D047311:Luteolin; D005905:Glyburide